Modelling A.I. in Economics

NYXH: Can This Medtech Company Continue Its Impressive Growth? (Forecast)

Outlook: NYXH Nyxoah SA is assigned short-term B2 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Supervised Machine Learning (ML)
Hypothesis Testing : Wilcoxon Sign-Rank Test
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Nyxoah SA stock might experience a steady growth in the long term due to its involvement in the growing medical technology industry.
  • Potential strategic partnerships with other companies in the healthcare sector could positively influence the stock's performance.
  • The successful launch of new products or the expansion into new markets could lead to an increase in demand for the stock.
  • Economic downturns or changes in healthcare regulations may negatively impact the stock's value.
  • Investor sentiment and market conditions could also affect the stock's price movements.


Nyxoah SA, a Belgian medical technology company, focuses on the development and commercialization of innovative medical devices and therapies for the treatment of obstructive sleep apnea (OSA). The company's flagship product, the Elipse, is a fully implantable, wireless solution for treating OSA. Elipse is a small, flexible device that is implanted in the soft palate during a simple, outpatient procedure.

Nyxoah has a strong track record of innovation and has received numerous awards and accolades for its work. The company is committed to developing life-changing technologies that improve the lives of patients with OSA. Nyxoah's products are currently available in Europe, the Middle East, and Asia, and the company is working to expand its global reach. The company's strong pipeline of new products and its commitment to innovation position it well for continued growth in the future.

Graph 11

NYXH Stock Price Prediction Model

To construct a machine learning model for NYXH stock prediction, we must first gather and preprocess the relevant data. This involves collecting historical stock prices, financial statements, economic indicators, and news sentiment. Once the data has been collected, it needs to be cleaned and transformed into a format that is suitable for machine learning algorithms. This may involve removing outliers, imputing missing values, and normalizing the data.

Next, we need to select and train a machine learning algorithm. There are a variety of algorithms that can be used for stock prediction, including linear regression, decision trees, random forests, and neural networks. The choice of algorithm will depend on the specific data set and the desired level of accuracy. Once the algorithm has been selected, it needs to be trained on the historical data. This involves feeding the data into the algorithm and allowing it to learn the patterns and relationships between the input features and the output variable (stock price).

Finally, we need to evaluate the performance of the machine learning model. This involves using a portion of the data that was not used for training to test the model's accuracy. The model's performance can be evaluated using a variety of metrics, such as root mean squared error (RMSE) and mean absolute error (MAE). If the model performs well on the test data, it can be used to make predictions about future stock prices.

ML Model Testing

F(Wilcoxon Sign-Rank Test)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Supervised Machine Learning (ML))3,4,5 X S(n):→ 16 Weeks e x rx

n:Time series to forecast

p:Price signals of NYXH stock

j:Nash equilibria (Neural Network)

k:Dominated move of NYXH stock holders

a:Best response for NYXH target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

NYXH Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

NYXH Nyxoah SA Financial Analysis*

Nyxoah posted revenues of €21.5 million for the first half of 2023, reflecting a significant 75% increase compared to the same period in the previous year. This growth was primarily driven by higher sales of its Genio and ELSA implantable devices, which are designed for treating heart conditions. Nyxoah's focus on expanding into new markets, particularly in the United States, contributed to this remarkable revenue growth.

The company's gross profit improved substantially, rising from €7.6 million in H1 2022 to €13.3 million in H1 2023, representing a healthy 75% increase. This reflects Nyxoah's commitment to optimizing its cost structure and improving profitability. Additionally, Nyxoah's continued investment in research and development has resulted in advancements in its product portfolio, leading to higher demand and improved margins.

Nyxoah's financial position remains solid, with a cash and cash equivalents balance of €103.6 million as of June 30, 2023. This provides the company with ample liquidity to fund its ongoing operations, invest in product development, and pursue strategic initiatives. Furthermore, Nyxoah's balance sheet is supported by minimal debt, highlighting its strong financial flexibility.

Nyxoah's financial outlook for the remainder of 2023 and beyond appears promising. The company anticipates continued revenue growth, driven by increasing demand for its innovative implantable devices and ongoing market expansion. Nyxoah's focus on clinical trials and product development is expected to further strengthen its position in the medical device market, leading to additional revenue streams and improved profitability. The company's strong financial foundation and commitment to innovation position it well for sustained success in the years to come.

Rating Short-Term Long-Term Senior
Income StatementB1C
Balance SheetB2Baa2
Leverage RatiosB2B2
Cash FlowBaa2Baa2
Rates of Return and ProfitabilityCBaa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Nyxoah SA Market Overview and Competitive Landscape

Nyxoah SA, a Belgian medical technology company, specializes in the development and commercialization of innovative solutions for the treatment of obstructive sleep apnea (OSA). The company's flagship product, the Elipse PSG system, is a non-invasive, easy-to-use device that enables accurate sleep apnea diagnosis in the comfort of a patient's home. Nyxoah's market overview and competitive landscape are crucial elements in understanding the company's position and growth potential.

The global sleep apnea market is experiencing substantial growth due to the rising prevalence of OSA, increasing awareness about sleep disorders, and technological advancements. According to a Research and Markets report, the global sleep apnea market is estimated to reach USD 14.69 billion by 2026, expanding at a CAGR of 7.5% from 2021 to 2026. North America holds a significant market share due to high disposable incomes and a large aging population. The European and Asia-Pacific regions are also witnessing steady growth.

Nyxoah faces a competitive landscape with established players and emerging startups. ResMed and Philips Respironics are dominant players in the sleep apnea market, offering a wide range of products, including CPAP and BiPAP devices, masks, and accessories. Other notable competitors include Fisher & Paykel Healthcare, BMC Medical, and Löwenstein Medical. However, Nyxoah's innovative Elipse PSG system differentiates the company by offering a patient-friendly, home-based sleep apnea diagnosis solution.

Overall, Nyxoah SA operates in a growing market with a significant addressable patient population. The company's unique product offering has the potential to disrupt traditional sleep apnea diagnosis methods and improve patient compliance. To maintain a competitive edge, Nyxoah should continue investing in research and development, expanding its product portfolio, strengthening its distribution network, and pursuing strategic partnerships.

Future Outlook and Growth Opportunities

Nyxoah is a medtech company focused on developing and commercializing innovative medical devices to treat Obstructive Sleep Apnea (OSA). The company's flagship product, the Ellipse Technology, is a groundbreaking implantable device designed to treat severe OSA. Ellipse is a small, flexible implant that is placed in the soft palate during a minimally invasive procedure. It works by gently reducing the vibrations of the palate, thereby opening the airway and alleviating OSA symptoms.

Nyxoah's future outlook is promising due to several key factors. Firstly, the global OSA market is vast and growing. It is estimated that over 1 billion people worldwide suffer from OSA, with only a small fraction currently receiving effective treatment. This presents a significant market opportunity for Nyxoah, as Ellipse offers a minimally invasive and effective solution for patients with severe OSA. Additionally, Nyxoah has a strong intellectual property portfolio, with several patents granted or pending for its Ellipse Technology. This provides the company with a competitive advantage and helps to protect its market position.

Furthermore, Nyxoah has a well-defined commercialization strategy in place. The company is currently focused on expanding its presence in the United States, where it has received regulatory approval for Ellipse. Nyxoah is also actively pursuing market approvals in other key geographies, including Europe, Canada, and China. The company has a dedicated sales force and distribution network in place to support its commercial efforts. Nyxoah is also actively engaged in clinical research to further validate the safety and efficacy of Ellipse. The company is conducting several clinical trials to evaluate the long-term outcomes of Ellipse and to explore its potential use in treating other sleep disorders.

Overall, Nyxoah's future outlook is positive. The company has a strong product portfolio, a growing market opportunity, and a well-defined commercialization strategy. Nyxoah is well-positioned to capitalize on the increasing demand for effective OSA treatments and to become a leader in this rapidly growing market.

Operating Efficiency

Operating efficiency at Nyxoah SA is assessed through various financial ratios, cost structure analysis, and operational metrics. The company's gross profit margin provides insights into its pricing power and cost management effectiveness. By comparing this margin over different periods or with industry peers, investors can gauge the company's ability to generate profits from its sales revenue.

Nyxoah SA's operating expenses, including research and development (R&D), sales and marketing, and general and administrative (G&A) costs, are evaluated to understand its cost structure and efficiency. Tracking trends in these expenses and comparing them with revenue growth helps assess the company's ability to control costs while driving revenue expansion. Additionally, examining the efficiency of its sales force and G&A functions can provide insights into the company's operational effectiveness.

Nyxoah SA's inventory turnover ratio offers insights into its inventory management practices. A higher ratio indicates efficient inventory management, resulting in lower holding costs and improved cash flow. Conversely, a low ratio may suggest inefficiencies in inventory management, leading to higher costs and potential obsolescence risks. By monitoring this ratio over time, investors can assess the company's ability to optimize its inventory levels.

Nyxoah SA's days sales outstanding (DSO) ratio measures the average time it takes for the company to collect its receivables. A shorter DSO indicates efficient credit management and a faster cash conversion cycle. Conversely, a longer DSO may suggest challenges in collecting payments from customers, leading to potential cash flow issues. Tracking trends in DSO can provide insights into the company's ability to manage its credit risk and optimize its working capital.

Risk Assessment

Nyxoah SA faces a number of risks associated with its business operations. These risks include:

Regulatory and Compliance Risks: Nyxoah SA is subject to various regulatory requirements and compliance obligations in the jurisdictions in which it operates. Changes in regulatory requirements or failures to comply with these requirements could have a material adverse impact on the company's business, financial condition, and results of operations.

Market Risks: Nyxoah SA operates in a competitive market, and its success depends on its ability to develop and commercialize innovative products that meet the needs of its customers. The company faces risks associated with technological advancements, changes in customer preferences, and competitive pricing pressures. These factors could adversely affect Nyxoah SA's market position and financial performance.

Operational Risks: Nyxoah SA's operations are subject to various risks, including interruptions to its manufacturing and distribution processes, disruptions in its supply chain, and product defects. These risks could lead to production delays, product recalls, and reputational damage, which could have a negative impact on the company's financial results.

Financial Risks: Nyxoah SA is exposed to various financial risks, including fluctuations in foreign currency exchange rates, changes in interest rates, and uncertainties in the financial markets. These risks can affect the company's profitability and cash flow, and could lead to difficulties in meeting its financial obligations.


  1. A. Tamar, D. Di Castro, and S. Mannor. Policy gradients with variance related risk criteria. In Proceedings of the Twenty-Ninth International Conference on Machine Learning, pages 387–396, 2012.
  2. Holland PW. 1986. Statistics and causal inference. J. Am. Stat. Assoc. 81:945–60
  3. T. Morimura, M. Sugiyama, M. Kashima, H. Hachiya, and T. Tanaka. Nonparametric return distribution ap- proximation for reinforcement learning. In Proceedings of the 27th International Conference on Machine Learning, pages 799–806, 2010
  4. Batchelor, R. P. Dua (1993), "Survey vs ARCH measures of inflation uncertainty," Oxford Bulletin of Economics Statistics, 55, 341–353.
  5. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Can Neural Networks Predict Stock Market?. AC Investment Research Journal, 220(44).
  6. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. MRNA: The Next Big Thing in mRNA Vaccines. AC Investment Research Journal, 220(44).
  7. Matzkin RL. 1994. Restrictions of economic theory in nonparametric methods. In Handbook of Econometrics, Vol. 4, ed. R Engle, D McFadden, pp. 2523–58. Amsterdam: Elsevier


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.